📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Kairos Pharma

1.1 - Company Overview

Kairos Pharma Logo

Kairos Pharma

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒
🌐 Website

Company description

  • Provider of clinical-stage cancer immunotherapies addressing drug resistance: ENV-105 (Endoglin-targeting antibody; Phase I/II for prostate and lung), KROS-201 (activated T cell therapy for glioblastoma), KROS-101 (GITR agonist), KROS-102 (GITR antagonist), KROS-301 (RelA/NF-ÎșB inhibitor), and KROS-401 (IL4/IL13 cyclic peptide for triple-negative breast cancer, with radiation).

Products and services

  • ENV-105: Clinical-stage antibody targeting Endoglin to reverse resistance in prostate and lung cancer treatments, with active Phase I and Phase II clinical trials
  • KROS-301: Small-molecule inhibitor blocking intranuclear RelA localization, targeting the NF-KB pathway to kill tumor cells in RelA/p65 biomarker-positive solid tumors
  • KROS-101: Small-molecule GITR agonist engineered to deplete regulatory T cells and activate effector T cells, enhancing the antitumor immune response

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Kairos Pharma

FogPharma Logo

FogPharma

HQ: United States Website
  • Description: Provider of precision medicines based on Helicons, a new class combining antibody-like targeting with broad tissue distribution and intracellular target engagement of small molecules; pipeline includes FOG-001, a first-in-class TCF-blocking ÎČ-catenin inhibitor (Phase 1/2), ÎČ-catenin and ERG degraders, an ERG/DNA binding inhibitor (discovery), and Helicon-enabled alpha radioligand therapies (hit identification).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full FogPharma company profile →
Theriva Biologics Logo

Theriva Biologics

HQ: United States Website
  • Description: Provider of biologics for the prevention and treatment of serious infectious diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Theriva Biologics company profile →
MAIA Biotechnology Logo

MAIA Biotechnology

HQ: United States Website
  • Description: Provider of immuno-oncology drug R&D, developing first-in-class therapies with novel mechanisms, including THIO, an investigational telomere-targeting candidate that induces immune responses in cancer cells (Phase 2 in non-small cell lung cancer), and second-generation telomere-targeting agents in early discovery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MAIA Biotechnology company profile →
IsoPlexis Logo

IsoPlexis

HQ: United States Website
  • Description: Provider of single-cell detection technology that identifies a wide range of patient immune responses at the single-cell level. Its platform assesses the safety and efficacy of therapeutics and monitors disease progression to support improved therapeutic development and inform physician decisions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full IsoPlexis company profile →
Ajax Therapeutics Logo

Ajax Therapeutics

HQ: United States Website
  • Description: Provider of therapies targeting cytokine signaling in hematologic malignancies, including AJ1-10502, a next-generation Type II JAK2 inhibitor for myeloproliferative neoplasms with improved efficacy and selectivity over Type I JAK2 inhibitors, and developer of a pipeline of selectively targeted small molecules via a partnership with Schrödinger using advanced computational chemistry and structure-based technologies.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Ajax Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Kairos Pharma

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Kairos Pharma

2.2 - Growth funds investing in similar companies to Kairos Pharma

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Kairos Pharma

4.2 - Public trading comparable groups for Kairos Pharma

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Kairos Pharma

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Kairos Pharma

What does Kairos Pharma do?

Kairos Pharma is a provider of clinical-stage cancer immunotherapies addressing drug resistance: ENV-105 (Endoglin-targeting antibody; Phase I/II for prostate and lung), KROS-201 (activated T cell therapy for glioblastoma), KROS-101 (GITR agonist), KROS-102 (GITR antagonist), KROS-301 (RelA/NF-ÎșB inhibitor), and KROS-401 (IL4/IL13 cyclic peptide for triple-negative breast cancer, with radiation).

Who are Kairos Pharma's competitors?

Kairos Pharma's competitors and similar companies include FogPharma, Theriva Biologics, MAIA Biotechnology, IsoPlexis, and Ajax Therapeutics.

Where is Kairos Pharma headquartered?

Kairos Pharma is headquartered in United States.

How many employees does Kairos Pharma have?

Kairos Pharma has 1,000 employees 🔒.

When was Kairos Pharma founded?

Kairos Pharma was founded in 2010 🔒.

What sector and industry vertical is Kairos Pharma in?

Kairos Pharma is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Kairos Pharma

Who are the top strategic acquirers in Kairos Pharma's sector and industry

Top strategic M&A buyers and acquirers in Kairos Pharma's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Kairos Pharma?

Top strategic M&A buyers groups and sectors for Kairos Pharma include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Kairos Pharma's sector and industry vertical

Which are the top PE firms investing in Kairos Pharma's sector and industry vertical?

Top PE firms investing in Kairos Pharma's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Kairos Pharma's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Kairos Pharma's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Kairos Pharma's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Kairos Pharma include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Kairos Pharma's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Kairos Pharma?

The key public trading comparables and valuation benchmarks for Kairos Pharma include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Kairos Pharma for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Kairos Pharma with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Kairos Pharma's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Kairos Pharma with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Kairos Pharma's' sector and industry vertical?

Access recent funding rounds and capital raises in Kairos Pharma's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Kairos Pharma